<DOC>
	<DOCNO>NCT00287937</DOCNO>
	<brief_summary>This phase I trial study side effect best dose vorinostat give together paclitaxel carboplatin treat patient advanced refractory solid tumor . Vorinostat may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , paclitaxel carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving vorinostat together paclitaxel carboplatin may kill tumor cell</brief_summary>
	<brief_title>Vorinostat , Paclitaxel , Carboplatin Treating Patients With Advanced Refractory Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine recommend phase II dose vorinostat ( SAHA ) administer paclitaxel carboplatin patient advance refractory solid tumor . SECONDARY OBJECTIVES : I . Determine dose-limiting toxicity ( DLT ) toxic effect regimen patient . II . Assess , preliminarily , evidence antitumor activity regimen patient . III . Determine pharmacokinetic parameter regimen patient . IV . Determine vivo effect regimen patient . OUTLINE : This multicenter , dose-escalation study vorinostat ( SAHA ) . Patients receive oral SAHA twice daily day 1-14* paclitaxel IV 3 hour follow carboplatin IV 30 minute day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients stable disease completion 6 course may receive single-agent SAHA discretion treat physician . NOTE : *During first treatment course , patient receive SAHA day -4 10.Cohorts 3-6 patient receive escalate dos SAHA maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience DLT . An additional 6-12 patient treat MTD . After completion study treatment , patient follow 1 month .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically confirm solid tumor No untreated brain metastasis Patients stable brain disease ( concurrent corticosteroid ) ≥ 4 week completion appropriate therapy eligible ECOG performance status ≤ 2 OR Karnofsky performance status 60100 % Life expectancy &gt; 12 week WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin normal AST/ALT ≤ 2.5 time upper limit normal Creatinine within normal institutional limit OR creatinine clearance ≥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective double barrier contraception least 1 week , , least 2 week study participation No peripheral neuropathy &gt; grade 1 No history allergic reaction paclitaxel No history allergic reaction attribute compound similar chemical biologic composition study drug No inability take oral medication continuous basis No psychiatric illness social situation would limit compliance study No ongoing active infection No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No uncontrolled illness No 2 prior chemotherapy regimens advanced/metastatic disease Adjuvant chemotherapy administer ≥ 2 year prior study entry consider prior chemotherapy regimen purpose study No prior therapy paclitaxel No chemotherapy radiotherapy within past 3 week ( 6 week nitrosoureas mitomycin C ) recover At least 4 week since prior valproic acid No concurrent anticancer therapy agents No concurrent investigational agent No concurrent combination antiretroviral therapy HIVpositive patient No concurrent oral contraceptives No concurrent prophylactic growth factor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>